 "Alkem, Dr Lal to make stock market debut on Dec 23")
Drug maker Alkem Laboratories and diagnostic chain Dr Lal PathLabs, which recently concluded initial public offerings successfully, would list their shares on the stock exchanges on Wednesday. The equity shares would be listed on the BSE and the National Stock Exchange. Alkem and Dr Lal PathLabs have raised about Rs 1,350 crore and Rs 191 crore, respectively.
Alkem has raised about Rs 1,350 crore at an issue price of Rs 1,050 per share from its IPO, which was oversubscribed 44.29 times. It plans to expand its footprint internationally.
It had a portfolio of 705 brands in the domestic market as on September 30.
Dr Lal's IPO too was a huge success with 33.41 times oversubscription. The price band was fixed at Rs 540-550 per share for the Rs 638 crore IPO. It also raised over Rs 191 crore from anchor investors by selling shares at Rs 550 apiece.
Alkem has raised about Rs 1,350 crore at an issue price of Rs 1,050 per share from its IPO, which was oversubscribed 44.29 times. It plans to expand its footprint internationally.
It had a portfolio of 705 brands in the domestic market as on September 30.
Dr Lal's IPO too was a huge success with 33.41 times oversubscription. The price band was fixed at Rs 540-550 per share for the Rs 638 crore IPO. It also raised over Rs 191 crore from anchor investors by selling shares at Rs 550 apiece.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%